First-line treatment with atezolizumab significantly improves the overall survival of platinum-ineligible patients with locally advanced or metastatic non-small-cell lung cancer relative to chemotherapy.

The novel KRAS inhibitor divarasib has shown promise in previously treated patients with advanced solid tumors harboring a KRAS G12C mutation.

Click through for more information about this lung cancer recommendation

Updated findings from the ARROW trial show that pralsetinib has “robust efficacy” for the first-line treatment of locally advanced or metastatic, RET fusion-positive, non-small-cell lung cancer, the investigators say.

The latest findings from an integrated analysis of three trials confirm the efficacy of entrectinib for patients with previously treated, locally advanced or metastatic ROS1 fusion-positive non-small-cell lung cancer, and point to a possible role as a first-line agent in this population.

Adding cemiplimab to first-line platinum-doublet chemotherapy significantly improves outcomes for patients with advanced non-small-cell lung cancer, regardless of tumor PD-L1 expression or histology, EMPOWER-Lung 3 study data show.

Supplementing first-line chemotherapy with the PD-1 inhibitor toripalimab significantly improves the progression-free survival and overall survival of patients with advanced non-small-cell lung cancer, suggest Chinese trial data.

Incidental irradiation of the sinoatrial node during lung cancer chemoradiotherapy may be associated with an increased risk for atrial fibrillation and death, research suggests.

This article summarizes the top-line results of the published trials of immunotherapeutic agents – used as monotherapy, in combination with chemotherapy, or as maintenance – in patients with previously untreated locally advanced or metastatic urothelial carcinoma.

Data from the BFAST study suggest that blood-based tumor mutational burden at a cutoff of 16 mutations does not predict first-line atezolizumab outcomes in people with advanced non-small-cell lung cancer.

Adding the PD-1 inhibitor sintilimab and the bevacizumab biosimilar IBI305 to chemotherapy significantly improves the progression-free survival of people with EGFR -mutated, nonsquamous non-small-cell lung cancer that has progressed after prior EGFR–tyrosine kinase inhibitor therapy, suggests an interim analysis of a Chinese phase 3 trial.

Discontinuation of immunosuppressive therapy may not be required for patients with a kidney transplant receiving immune checkpoint inhibitor therapy for advanced cancer, indicates preliminary research published in The Lancet Oncology .

Previously untreated patients with PD-L1-positive advanced non-small-cell lung cancer could benefit from the combination of tiragolumab plus atezolizumab, indicate phase 2 trial data.

First-line treatment with the third-generation EGFR–tyrosine kinase inhibitor aumolertinib significantly improves progression-free survival relative to gefitinib in people with advanced non-small-cell lung cancer and sensitizing EGFR mutations, indicate Chinese trial data.

The PD-L1 inhibitor sugemalimab has shown potential both as a consolidation treatment option for inoperable, locally advanced non-small-cell lung cancer as well as in combination with chemotherapy for the first-line treatment of metastatic disease.

The KRAS G12C inhibitor sotorasib has durable efficacy and manageable safety in previously treated patients with KRAS -mutated, advanced non-small-cell lung cancer, suggests long-term follow-up of the CodeBreaK 100 trial.

Individuals with unresectable locally advanced non-small-cell lung cancer and no progression after chemoradiotherapy could benefit from the addition of the CD73 inhibitor oleclumab or the NKG2A-targeted agent monalizumab to consolidation durvalumab, suggest phase 2 results.